SCHEMBL23795372

SCHEMBL23795372

CCC1CNCCCN1S(=O)(=O)c1cccc2c(OC)nccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 9/20 0.45
▸ ROCK2 O75116 8/20 0.45
▸ PRKCD Q05655 6/20 0.45
▸ PRKCE Q02156 4/20 0.45
▸ PRKD1 Q15139 4/20 0.45
▸ PRKX P51817 3/20 0.45
▸ PRKACA P17612 6/20 0.41
▸ PRKACG P22612 5/20 0.41
▸ PRKACB P22694 5/20 0.41
▸ PRKD3 O94806 4/20 0.41
▸ PRKCZ Q05513 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ CYP3A4 P08684 4/20 0.41
▸ CYP2D6 P10635 4/20 0.41
▸ PRKCG P05129 3/20 0.41
▸ PRKCB P05771 3/20 0.41
▸ PRKCA P17252 3/20 0.41
▸ PRKCH P24723 3/20 0.41
▸ PRKCI P41743 3/20 0.41
▸ PRKCQ Q04759 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30439464 1.00 ROCK1 (0.45) ROCK1ROCK2PRKCDPRKCEPRKD1
SCHEMBL30439073 1.00 ROCK1 (0.45) ROCK1ROCK2PRKCDPRKCEPRKD1
SCHEMBL23795370 1.00 ROCK1 (0.45) ROCK1ROCK2PRKCDPRKCEPRKD1
SCHEMBL30439456 0.91 ROCK1 (0.42) ROCK1ROCK2PRKCDPRKCEPRKD1
SCHEMBL23795330 0.91 ROCK1 (0.42) ROCK1ROCK2PRKCDPRKCEPRKD1
SCHEMBL30439350 0.91 ROCK1 (0.42) ROCK1ROCK2PRKCDPRKCEPRKD1
SCHEMBL23795312 0.91 ROCK1 (0.42) ROCK1ROCK2PRKCDPRKCEPRKD1
Hydrochloric Acid SCHEMBL23795326 0.90 ROCK2 (0.41) ROCK1ROCK2PRKCDPRKCEPRKD1
Hydrochloric Acid SCHEMBL23795425 0.90 ROCK2 (0.41) ROCK1ROCK2PRKCDPRKCEPRKD1
Hydrochloric Acid SCHEMBL30439869 0.90 ROCK2 (0.41) ROCK1ROCK2PRKCDPRKCEPRKD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264146-B2 Rho kinase inhibitor, method for preparing same and uses thereof BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2025-04-01 — — US claimed
US-12264146-B2 Rho kinase inhibitor, method for preparing same and uses thereof BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2025-04-01 — — US disclosed
CN-111116555-B Rho kinase inhibitor and preparation method and application thereof 北京盈科瑞创新药物研究有限公司 2023-06-02 — — CN disclosed
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2022-01-06 — — US disclosed
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2022-01-06 — — US disclosed
EP-3878846-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF Beijing Increase Innovative Drug Co., Ltd. (CN) 2021-09-15 — — EP disclosed
EP-3878846-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF Beijing Increase Innovative Drug Co., Ltd. (CN) 2021-09-15 — — EP disclosed
CN-111116555-A Rho kinase inhibitor and preparation method and application thereof 北京盈科瑞创新药物研究有限公司 2020-05-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF ROCK1, RHOA, ROCK2 ROCK1 1/4885ROCK2 3/4885PRKCD 517/4885
US-12264146-B2 Rho kinase inhibitor, method for preparing same and uses thereof ROCK1, RHOA, ROCK2 ROCK1 1/4885ROCK2 3/4885PRKCD 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback